- Home
- PRMB vs MRNA Comparison
PRMB vs MRNA Comparison
Compare PRMB & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRMB
- MRNA
- Stock Information
- Founded
- PRMB 1955
- MRNA 2010
- Country
- PRMB United States
- MRNA United States
- Employees
- PRMB N/A
- MRNA N/A
- Industry
- PRMB
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRMB
- MRNA Health Care
- Exchange
- PRMB Nasdaq
- MRNA Nasdaq
- Market Cap
- PRMB 8.4B
- MRNA 9.8B
- IPO Year
- PRMB N/A
- MRNA 2018
- Fundamental
- Price
- PRMB $22.03
- MRNA $26.11
- Analyst Decision
- PRMB Buy
- MRNA Hold
- Analyst Count
- PRMB 12
- MRNA 15
- Target Price
- PRMB $36.25
- MRNA $40.46
- AVG Volume (30 Days)
- PRMB 3.9M
- MRNA 9.7M
- Earning Date
- PRMB 11-06-2025
- MRNA 11-06-2025
- Dividend Yield
- PRMB 1.81%
- MRNA N/A
- EPS Growth
- PRMB N/A
- MRNA N/A
- EPS
- PRMB N/A
- MRNA N/A
- Revenue
- PRMB $6,046,100,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- PRMB $33.59
- MRNA N/A
- Revenue Next Year
- PRMB $4.00
- MRNA $10.45
- P/E Ratio
- PRMB N/A
- MRNA N/A
- Revenue Growth
- PRMB 26.25
- MRNA N/A
- 52 Week Low
- PRMB $21.37
- MRNA $23.15
- 52 Week High
- PRMB $35.85
- MRNA $57.69
- Technical
- Relative Strength Index (RSI)
- PRMB 41.66
- MRNA 47.56
- Support Level
- PRMB $21.37
- MRNA $26.01
- Resistance Level
- PRMB $22.69
- MRNA $28.48
- Average True Range (ATR)
- PRMB 0.54
- MRNA 1.38
- MACD
- PRMB 0.16
- MRNA -0.05
- Stochastic Oscillator
- PRMB 50.00
- MRNA 31.56
About PRMB Primo Brands Corporation Class A Common Stock
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.